BNET Industries
Market Cap:$150.0M
Last Fiscal Year Sales:$52.8M
- Public
- US
Dow Jones Description
Akorn, Inc. manufactures and markets sterile specialty pharmaceuticals. Akorn has manufacturing facilities located in Decatur, Illinois and Somerset, New Jersey and markets and distributes an extensive line of hospital and ophthalmic pharmaceuticals.
Interim Chief Executive Officer
Rajat RaiNumber of Employees 351
Peer Companies
NAICS Code Pharmaceutical Preparation Manufacturing: 325412
Recent Events
-
Akorn AKRX Posts Q3 Loss of $0.06, Beats By 2c
-
Akorn Slips To Q3 Loss - Update
-
Akorn, Inc. AKRX Acquires Eli Lilly's LLY Capastat Sulfate
-
Akorn Acquires Capastat Sulfate from Eli Lilly and Company
-
Sarnova Names Hank Struik Chief Executive Officer
-
Company and People Notes: CSL and Talecris Terminate Merger Agreement; Eli Lilly Hires Former Indianapolis...
-
Former Option Care Executives Take Management Posts At Akorn
-
Akorn Announces Management Changes
-
Akorn Named Rai As Interim CEO, Dick As CFO
News & Analysis
Filter by
akorn inc. and fda - All News and Analysis
Akorn-Strides, LLC Announces FDA Approval for Pamidronate Disodium Injection, 3 mg/mL and 9 mg/mL
LAKE FOREST, Ill. -- Akorn-Strides, LLC today announced that the U.S. Food and Drug Administration has granted approval for an Abbreviated New Drug Application ANDA for Pamidronate Disodium Injection, 3 mg/mL and 9 mg/mL in 10 mL vials. Akorn-Strides, LLC is a Joint Venture that was formed in 2004 by...
Akorn-Strides, LLC Announces FDA Approvals for Dexamethasone Sodium Phosphate Injection USP, 4 mg /mL and Dexamethasone Sodium Phosphate Injection USP, 10 mg /mL
BUFFALO GROVE, Ill. -- Akorn-Strides, LLC today announced the approval of two ANDAs for Dexamethasone Sodium Phosphate Injection USP, 4 mg base/mL in 1mL, 5 mL, and 30 mL vials, and Dexamethasone Sodium Phosphate Injection USP, 10 mg base/mL in 10 mL vials. Akorn-Strides, LLC is a Joint Venture that...
Akorn-Strides, LLC Announces FDA Approvals for Famotidine Injection USP, 20 mg/2mL Single-Dose Vials and Famotidine Injection USP, 40 mg/4mL & 200 mg/20 mL Multiple-Dose Vials
BUFFALO GROVE, Ill. -- Akorn-Strides, LLC today announced the approvals of two ANDAs for Famotidine Injection USP, 20 mg/2mL Single-Dose Vials and 40 mg/4mL & 200 mg/20mL Multiple-Dose Vials. Akorn-Strides, LLC is a Joint Venture that was formed in 2005 by Akorn, Inc. (NASDAQ: AKRX) and Strides Arcolab Limited (NSE:...
Akorn-Strides, LLC Announces FDA Approval for Rifampin for Injection USP, 600 mg/Vial
BUFFALO GROVE, Ill. -- Akorn-Strides, LLC today announced the approval of an ANDA for Rifampin for Injection USP, 600 mg/vial. This is the first lyophilized Injectable product approval for the Joint Venture. Akorn-Strides, LLC is a Joint Venture that was formed in 2005 by Akorn, Inc. (NASDAQ: AKRX) and...
Akorn-Strides, LLC Announces FDA Approval for Flumazenil Injection USP, 0.1 mg/mL - 5mL and 10 mL Multiple Dose Vials
BUFFALO GROVE, Ill. -- Akorn-Strides, LLC today announced the approval of an ANDA for Flumazenil Injection USP, 0.1 mg/mL, packaged in 5 mL and 10 mL Multiple Dose Vials. Akorn-Strides, LLC is a Joint Venture that was formed in 2005 by Akorn, Inc. (NASDAQ:AKRX) and Strides Arcolab Limited (NSE:STAR) (BSE:532531)....
Akorn-Strides, LLC Announces FDA Approvals for Ondansetron Injection USP, 4 mg/2mL Single Dose Vials and Ondansetron Injection USP, 40 mg/20mL Multiple Dose Vials
BUFFALO GROVE, Ill. -- Akorn-Strides, LLC today announced the approvals of two ANDAs for Ondansetron Injection USP, 4 mg/2mL Single Dose Vials and Ondansetron Injection USP, 40 mg/20mL Multiple Dose Vials. Akorn-Strides, LLC is a Joint Venture that was formed in 2005 by Akorn, Inc. (NASDAQ: AKRX) and Strides Arcolab...
Akorn-Strides, LLC Announces FDA Approval for Fosphenytoin Sodium Injection USP, 100 mg/2mL and 500 mg/10mL
BUFFALO GROVE, Ill. -- Akorn-Strides, LLC today announced the approval of an ANDA for Fosphenytoin Sodium Injection USP, 100 mg/2mL and 500 mg/10mL equivalent to Phenytoin Sodium. Akorn-Strides, LLC is a Joint Venture that was formed in 2005 by Akorn, Inc. (NASDAQ:AKRX) and Strides Arcolab Limited (NSE:STAR) (BSE:532531). The primary...
Akorn-Strides, LLC Announces FDA Approval for Tobramycin Injection USP, 80 mg/2mL and 1.2 grams/30mL
BUFFALO GROVE, Ill. -- Akorn-Strides, LLC today announced the approval of an ANDA for Tobramycin Injection USP, 80 mg/2mL and 1.2 grams/30mL. Akorn-Strides, LLC is a Joint Venture that was formed in 2005 by Akorn, Inc. (NASDAQ: AKRX) and Strides Arcolab Limited (NSE: STAR, BSE: 532531). The primary mission for...
Akorn, Inc. and Strides Arcolab Limited Announce the Signing of a Definitive Agreement to Enter into a Joint Venture
BUFFALO GROVE, Ill. & BANGALORE, India -- Akorn, Inc. (OTCBB:AKRN.OB) Akorn and Strides Arcolab Limited Strides, one of India's largest manufacturers and exporters of pharmaceutical products, today announced the formation of a Joint Venture. The two companies had entered into a memorandum of understanding in April 2004 to enter into...
- 1
Decision Makers
| Name (plus bio) | Position |
|---|---|
| Rajat Rai | Interim Chief Executive Officer |
| Timothy A. Dick | Chief Financial Officer |
| Abu Alam | Senior Vice President, Res |
| John R. Sabat | Senior Vice President of National Accounts & Trade Relations |
| David White | Vice President, New Prod Development |
| Jay Stern | Vice President, Contract Manufacturing |
| Mark M. Silverberg | Vice President, Global Quality & Regulatory Compliance |
| Marshall Goodwin | Vice President, Global Quality & Regulatory Compliance |
| Neill Shanahan | Vice President, HR |
| Russell A. Gall | Vice President & General Manager, Operations |
| Chris Vogel | Manager, Sales |
| Joseph Bonaccorsi | Senior Vice President, General Counsel & Secretary |
| Michael P Stehn |
Board of Directors
| Name (plus bio) | Position |
|---|---|
| John N. Kapoor | Chairman |
| Arjun C. Waney | Board of Directors |
| Jerry I. Treppel | Board of Directors |
| Jerry N. Ellis | Board of Directors |
| Ronald M. Johnson | Board of Directors |
| Organization | Position | Status |
|---|---|---|
| Akorn, Inc. | Interim Chief Executive Officer | Current |
| Missouri River Hospice | Board of Directors | Current |
| Sequal Technologies, Inc. | Director | Current |
| Salient Business Solutions Limited | Board of Directors | Current |
| Walgreen Option Care | Chief Executive Officer | Former |
| Option Care of Sparta | President & Chief Executive Officer | Former |
| Walgreen Option Care | President | Former |
| Walgreen Option Care | Executive Vice President of Operations | Former |
| Walgreen Option Care | Board of Directors | Former |
| Wayne State University | M.B.A. In Finance | Former |
| Organization | Position | Status |
|---|---|---|
| Akorn, Inc. | Chief Financial Officer | Current |
* An accomplished executive in the pharmaceutical industry with over 35 years experience. Dr. Alam joined Akorn in 1997. * Dr. Alam has a strong technical background with respect to Chemistry Manufacturing and Control, Preclinical and Clinical research on drug development including putting deals with global and domestic partners. * Prior to Akorn, Dr. Alam held many Senior Management positions in the pharmaceutical industry and venture businesses such as: EJ Financial, Lyphomed, Fujisawa, American Critical Care, Adria Laboratories, Rohm & Haas and Warren-Teed. * Dr. Alam served as management consultant to NeoPharm, Carbomed, Criticare and Unimed. * Credentials include presentations to the FDA Advisory Committees, 40 published papers, abstracts and presentations; 14 US patents and an adjunct professor at the University of Illinois. * Dr. Alam is on the Editorial Board of American Pharmaceutical Outsourcing. * Holds a B.S. degree in Pharmacy from Philadelphia College of Pharmacy & Science, M.S. and Ph.D. from University of Iowa.
| Organization | Position | Status |
|---|---|---|
| Akorn, Inc. | Senior Vice President, Res | Current |
| APP Pharmaceuticals, Inc. | Former | |
| Rohm & Haas Company | Former | |
| NeoPharm, Inc. | Former |
- With a career encompassing over 32 years in the Pharmaceutical industry, Mr. Sabat is widely recognized as a leader and one of the premier National Account executives in the pharmaceutical industry.
| Organization | Position | Status |
|---|---|---|
| Akorn, Inc. | Senior Vice President of National Accounts & Trade Relations | Current |
| Gold Line Corporation | Former |
| Organization | Position | Status |
|---|---|---|
| Akorn, Inc. | Vice President, New Prod Development | Current |
- Holding variety of progressively responsible leadership positions in the healthcare industry, Mr. Stern brings to Akorn a proven, successful track record of over 17 years of experience in the pharmaceutical and medical device areas.
| Organization | Position | Status |
|---|---|---|
| Akorn, Inc. | Vice President, Contract Manufacturing | Current |
| VHA Inc. | Former |
* An accomplished multi-disciplinary executive with 34 years experience, Mr. Silverberg joined Akorn in April 2005. * Mr. Silverberg directs Akorn's manufacturing operations, global Quality Assurance and Research and Development programming. He is responsible for the company's drug product formulation, filling and packaging facilities, warehousing and distribution, Quality / Microbiological / R&D laboratories, as well as Regulatory Compliance / Regulatory Affairs and relationship management with FDA and other domestic and international regulatory authorities. * Mr. Silverberg joined Akorn after a successful, thirty-year career at Abbott Laboratories, where he served at the Director level in several division and corporate level positions – including the Hospital Product Divisions (HPD), Pharmaceutical Products Division (PPD), Abbott Diagnostics Division (ADD) and Corporate Quality Assurance / Regulatory Affairs. * He directed divisional and corporate support activities for large volume, small volume injectable products and oral dosage drugs, as well as medical device product lines. * He holds a B.S. Biology from Marquette University.
| Organization | Position | Status |
|---|---|---|
| Akorn, Inc. | Vice President, Global Quality & Regulatory Compliance | Current |
| Organization | Position | Status |
|---|---|---|
| Akorn, Inc. | Vice President, Global Quality & Regulatory Compliance | Current |
* With over 20 years of broad-based experience in employee relations, training, compensation/benefits design and administration, Mr. Shanahan joined Akorn in 2000 as the company’s first Human Resources executive. * Mr. Shanahan has supported substantial business units, including both headquarters and operating groups and he has led plant start-up teams. * Prior to joining Akorn, he has held progressively responsible management positions in the Human Resources field including: o Manager, Human Resources at Qualex Inc, a subsidiary of Eastman Kodak, where he supported 25 high-volume, technology-based photo-finishing plants, 4000 employees and $600 million in sales. o Additionally, Mr. Shanahan held several positions with Emery Worldwide, Inc, a subsidiary of CNF Inc., where he supported US and Canadian operations with 1500 employees and $400 million in sales. At Emery, Mr. Shanahan developed and implemented manpower planning and management training programs on a corporate level.
| Organization | Position | Status |
|---|---|---|
| Akorn, Inc. | Vice President, HR | Current |
| Con-Way Inc. | Former |
| Organization | Position | Status |
|---|---|---|
| Akorn, Inc. | Vice President & General Manager, Operations | Current |
| Organization | Position | Status |
|---|---|---|
| Akorn, Inc. | Manager, Sales | Current |
| Organization | Position | Status |
|---|---|---|
| Akorn, Inc. | Senior Vice President, General Counsel & Secretary | Current |
| Walgreen Option Care | General Counsel | Current |
| Missouri River Hospice | Board of Directors | Current |
| Walgreen Option Care | Senior Vice President | Former |
| Walgreen Option Care | Secretary | Former |
| Loyola University Chicago | Juris Doctor Degree | Former |
| Northwestern University | Bachelor of Science Degree | Former |
* In this position, he provides overall management and leadership to the Manufacturing, Engineering and Contract Services departments and is responsible for strategic and operational planning. * Prior to joining Akorn in 1990, Mr. Stehn served as director of quality assurance and regulatory compliance with Carlisle Laboratories, a division of Rugby Darby. Mr. Stehn spent 11 years in various quality and regulatory positions with Carlisle Laboratories and has over 25 years of combined experience within the sterile pharmaceutical industry including SVP's, ointments, gels and medical devices. * Mr. Stehn holds a bachelor's degree in science with an emphasis on Microbiology and Clinical Chemistry from Fairleigh Dickinson University. He serves as a member of the Parenteral Drug Association.
| Organization | Position | Status |
|---|---|---|
| Akorn, Inc. | Current | |
| Fairleigh Dickinson University | bachelor's degree in science with an emphasis on Microbiology and Clinical Chemistry | Former |
John N. Kapoor is a co-founder of Insys and has served as the Chairman of our board of directors since our inception. Dr. Kapoor has served as the President and Chairman of the board of directors of EJ Financial Enterprises, since forming the company in 1990. Dr. Kapoor is also the Managing Partner of Kapoor-Pharma Investments, an investment company that he founded in 2000. Dr. Kapoor serves as the chairman of the board of directors of Akorn, a publicly traded specialty pharmaceutical company, where he served as the Chief Executive Officer from March 2001 to December 2002 and from May 1996 to November 1998. Dr. Kapoor also serves as the chairman of the board of directors of Option Care, a specialty pharmaceutical services company, where he served as Chief Executive Officer from August 1993 to April 1996. In addition, Dr. Kapoor serves as chairman of the board of directors of NeoPharm and serves as a member of the board of directors of Introgen Therapeutics, both publicly traded biopharmaceutical companies. Dr. Kapoor received his Ph.D. in medicinal chemistry from the State University of New York at Buffalo and a B.S. in pharmacy from Bombay University in India.
| Organization | Position | Status |
|---|---|---|
| Insys Therapeutics, Inc | Co-Founder | Current |
| Walgreen Option Care | Chairman of the Board of Directors | Current |
| Introgen Therapeutics, Inc. | Chairman of the Board of Directors | Current |
| NeoPharm, Inc. | Chairman of the Board of Directors | Current |
| Missouri River Hospice | Chairman | Current |
| Akorn, Inc. | Chairman | Current |
| Akorn, Inc. | Chairman | Current |
| Walgreen Option Care | Chief Executive Officer | Former |
| Walgreen Option Care | President | Former |
| S-Board Ltd. | Chairman | Former |
| Introgen Therapeutics, Inc. | Board of Directors | Former |
| State University of New York at Buffalo | Ph.D. In Medicinal Chemistry | Former |
| The State University of New York | Ph.D. In Medicinal Chemistry | Former |
| Bombay University | B.S. Degree | Former |
| Organization | Position | Status |
|---|---|---|
| Akorn, Inc. | Board of Directors | Current |
| Organization | Position | Status |
|---|---|---|
| Elite Pharmaceuticals, Inc. | Board of Directors | Current |
| Akorn, Inc. | Board of Directors | Current |
| Merrill Lynch & Co., Inc. | Healthcare Services Analyst | Former |
| Able Laboratories, Inc. | Board of Directors | Former |
| Organization | Position | Status |
|---|---|---|
| Akorn, Inc. | Board of Directors | Current |
| Organization | Position | Status |
|---|---|---|
| Akorn, Inc. | Board of Directors | Current |
Industry Transcripts by Seeking Alpha
-
Avanir Pharmaceuticals F4Q09 (Qtr End 09/30/2009) Earnings Call Transcript
on Nov 24, 2009about AVNR
-
Palatin Technologies F1Q10 (Qtr End 9/30/09) Earnings Call Transcript
on Nov 16, 2009about PTN
-
Flamel Technologies SA Q3 2009 Earnings Call Transcript
on Nov 16, 2009about FLML
-
NexMed Inc. Q3 2009 Earnings Call Transcript
on Nov 10, 2009about NEXM
-
InterMune, Inc. Q3 2009 Earnings Call Transcript
on Nov 10, 2009about ITMN
IndustryTop Rated
- How NOT to Write a Biotech Press Release: Just Ask Epeius 5 votes
- Fired Whistleblower Reps Make Similar Claim: Pfizer Said They Lacked "Integrity" 3 votes
- BioCryst's Antiviral Drug Peramivir Aims to Keep Swine-Flu Body Count Low 3 votes
- Why J&J's Stelara Launch Should Target Dermatologists First 3 votes
- VeriChip TV Ad Confirms Critics' Fears: They Want Everyone Implanted 3 votes

